Global Impact of Recent Clinical Evidence in Diabetic Macular Edema and Retinopathy Recent Clinical Evidence

Please answer the questions below and click submit. You will then be directed to view the manuscript. After reviewing the manuscript you'll be prompted to answer these questions again and receive 1 hour of CME credit.

*1. Effective treatment options for patients with proliferative diabetic retinopathy include (check all that apply):

a. Aflibercept b. Bevacizumab c. Ranibizumab d. Panretinal photocoagulation

*2. Based on 2-year area under the curve results, visual acuity was significantly better with aflibercept than with bevacizumab or ranibizumab in eyes with worse baseline visual acuity.

a. True b. False

*3. The increase in APTC events with ranibizumab is likely

a. Clinically relevant. b. A statistical anomaly. c. Relevant if the patient had an event 2 years ago. d. The result of systemic anti-VEGF.

*4. The ideal candidate with proliferative diabetic retinopathy for Protocol S anti-VEGF therapy:

a. Would be willing to come in monthly for anti-VEGF injections. b. Has bilateral disease. c. Does not have diabetic macular edema. d. Has no apparent iris neovascularization.

*5. Laser rescue therapy as used in Protocol T is commonly used in clinical practice to treat diffuse diabetic macular edema.

a. True b. False